VYNE Therapeutics Inc. (VYNE)
1.69
-0.09 (-5.06%)
At close: Mar 28, 2025, 3:59 PM
1.69
0.00%
After-hours: Mar 28, 2025, 04:37 PM EDT
VYNE Therapeutics Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
| Cash & Equivalents | 19.93M | 30.62M | 30.91M | 42.25M | 57.56M | 30.78M | 49.51M | 10.21M | 4.03M | 43.81M |
| Short-Term Investments | 41.59M | 62.63M | n/a | n/a | 1.03M | 46.17M | 86.74M | 49.3M | 26.88M | n/a |
| Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2.98M | 10.42M | n/a |
| Other Long-Term Assets | 2.26M | 1.51M | 2.2M | 3.51M | 4.34M | 73K | 282K | n/a | 66K | n/a |
| Receivables | n/a | n/a | 5M | 7.58M | 15.82M | n/a | n/a | 786K | n/a | n/a |
| Inventory | n/a | n/a | 97K | 7.29M | 7.4M | 1.36M | n/a | -2.98M | n/a | n/a |
| Other Current Assets | 2.92M | 2.71M | 2.37M | 6.06M | 4.59M | 1.38M | 6.5M | 3.57M | 632K | 77K |
| Total Current Assets | 64.44M | 95.96M | 38.27M | 63.19M | 87.26M | 78.33M | 139.5M | 63.86M | 31.54M | 43.88M |
| Property-Plant & Equipment | 206K | 207K | 282K | 354K | 2.14M | 769K | 146K | 28K | 27K | n/a |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 2.47M | 1.72M | 2.48M | 3.86M | 6.48M | 842K | 428K | 3.01M | 10.51M | n/a |
| Total Assets | 66.91M | 97.69M | 40.76M | 67.05M | 93.74M | 79.17M | 139.93M | 66.87M | 42.05M | 43.88M |
| Account Payables | 2.71M | 1.66M | 2.39M | 6.51M | 4.78M | 3.77M | 3.29M | 2.46M | 1.53M | 637K |
| Deferred Revenue | n/a | n/a | n/a | n/a | 15.81M | 5.71M | n/a | 1.8M | 1.8M | n/a |
| Short-Term Debt | 99K | 115K | n/a | 698K | 1.51M | 700K | n/a | n/a | n/a | n/a |
| Other Current Liabilities | 12.01M | 5.76M | 6.96M | 11.2M | 15.16M | 6.19M | 6.25M | 3.56M | 581K | 133K |
| Total Current Liabilities | 14.82M | 7.54M | 9.35M | 18.41M | 21.45M | 10.66M | 9.54M | 7.82M | 3.9M | 770K |
| Long-Term Debt | n/a | 99K | n/a | n/a | 34.03M | n/a | n/a | n/a | n/a | n/a |
| Other Long-Term Liabilities | n/a | 1.31M | 211K | n/a | 769K | n/a | 7K | 109.35M | 59.06M | 59.07M |
| Total Long-Term Liabilities | n/a | 1.41M | 211K | n/a | 34.8M | 34.26M | 7K | 116.08M | 67.59M | 59.07M |
| Total Liabilities | 14.82M | 8.95M | 9.56M | 18.41M | 56.25M | 10.66M | 9.55M | 123.9M | 71.49M | 59.84M |
| Total Debt | 99K | 214K | -349K | 349K | 34.78M | 700K | n/a | n/a | n/a | n/a |
| Common Stock | 1K | 1K | 1.47M | 5K | 4K | 3K | 3K | 1K | 1K | 1K |
| Retained Earnings | -731.17M | -691.34M | -662.74M | -639.52M | -566.2M | -184.34M | -110.64M | -59.19M | -30.11M | -16.05M |
| Comprehensive Income | 20K | 26K | n/a | n/a | n/a | 24K | -96K | -51K | -26K | -59M |
| Shareholders Equity | 52.09M | 88.73M | 31.2M | 48.64M | 37.49M | 68.51M | 130.38M | -57.03M | -29.44M | -15.95M |
| Total Investments | 41.59M | 62.63M | n/a | n/a | 1.03M | 46.17M | 86.74M | 52.27M | 37.3M | n/a |